Lilly’s oral GLP-1 traction

Eli Lilly’s new obesity pill Foundayo logged 1,390 U.S. prescriptions in its first week, giving the company an early foothold in the race to sell weight-loss drugs as tablets instead of shots. (pharmexec.com) Foundayo, the brand name for orforglipron, won U.S. Food and Drug Administration approval on April 1, 2026, for adults with obesity or overweight plus weight-related medical problems. Lilly said prescriptions were accepted immediately through LillyDirect and shipping began April 6. (investor.lilly.com) A glucagon-like peptide-1 drug mimics a gut hormone that helps people feel full and slows how quickly food leaves the stomach. Lilly says Foundayo is the only approved weight-loss GLP-1 pill that can be taken any time of day without food or water restrictions. (prnewswire.com) Clarivate put orforglipron and Lilly’s injectable candidate retatrutide on its 2026 “Drugs to Watch” list, arguing that Lilly’s next wave of obesity medicines could shape the market through the next decade. Clarivate said retatrutide is expected to be ready for launch in 2028. (clarivate.com) Retatrutide is not just another GLP-1 medicine. Clarivate described it as a triple-acting drug that targets GLP-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, a mix aimed at pushing weight loss beyond current therapies. (clarivate.com) Lilly is pitching convenience as the selling point for pills, but coverage still sets the ceiling. On Lilly’s current savings page, eligible commercially insured patients can pay as little as $25 a month, while self-pay prices start at $149 a month depending on dose. (foundayo.lilly.com) Insurance rules remain uneven, especially in government programs. KFF said on April 22 that Medicare is still generally barred by law from covering drugs used specifically for weight loss, and many Medicaid patients can face the full cash price unless states choose to cover them. (kff.org) Lilly has tried to get ahead of that barrier. In a November 6, 2025 news release, the company said it had reached an agreement with the U.S. government aimed at giving Medicare beneficiaries access to Zepbound and, if approved, orforglipron for no more than $50 a month starting as early as April 1, 2026. (lilly.com) The launch is also arriving with extra FDA scrutiny. The agency’s approval letter and follow-up coverage show Lilly must run post-marketing studies on risks including heart attack, stroke, liver injury, delayed stomach emptying, thyroid cancer follow-up, and exposure during pregnancy and childhood. (accessdata.fda.gov; pharmexec.com) Lilly’s own latest data are part of the sales pitch. In topline Phase 3 results released last week, the company said ACHIEVE-4 added cardiovascular safety data to a program that now spans seven Phase 3 studies and more than 11,000 patients. (investor.lilly.com) The first-week prescription number is small next to the millions of Americans eligible for obesity treatment, but it gives Lilly proof that a once-daily pill can draw immediate demand. The next test is whether payers keep the door open long enough for that demand to scale. (pharmexec.com; kff.org)